Olaparib-related seronegative inflammatory arthritis: first report in the literature

Cancer is among the most common causes of death worldwide. Recently, revolutionary targeted smart drugs have been used in the treatment of various malignancies. One of these intelligent molecules is PARP inhibitors, which have the ability to interfere with DNA damage repair systems (1). PARPs are an enzyme family of 17 members, of which PARP1 is the best described protein. PARP1 plays a critical role in the base excision–repair pathway that controls the repair of single-strand breaks in DNA. Olaparib is the most studied PARP inhibitor, with activity against PARP1 and PARP2 (2). Many studies have demonstrated the efficacy and safety of olaparib in the treatment of ovarian, breast, and stomach cancers (3). No musculoskeletal system side effects associated with olaparib have been reported in the literature. Herein, we report the development of olaparib-related seronegative arthritis in a female patient with ovarian cancer.